As another year comes to a close, we find ourselves reflecting on the achievements, milestones and moments that have shaped us. 2025 has been transformative and filled with milestones that have strengthened The Adjutor Group and positioned us for even greater success heading into 2026.
As we look back on the past year at The Adjutor Group, we’re proud to reaffirm what drives us: helping life-science innovators, especially smaller and medium-sized enterprises, turn ideas into real medicines, devices, and therapies that can improve lives.
From early-stage development and clinical trials to regulatory approval and global commercialisation, we work in partnership with our clients as an extension of their team.
The Adjutor Group is known for its commitment to excellence and client satisfaction, grounded in a set of core principles. This year has underscored that mission, and set the stage for even greater impact ahead. More than a service provider, we operate as your strategic partner.
Christmas and New Year Shutdown
Please note that all Adjutor offices will be closed for the holidays from COB on 23 December, reopening on 05 January 2026. Best wishes to all our clients, colleagues and friends for a wonderful Christmas and a Happy New Year.
This has been a transformative year for Adjutor, becoming a group of companies providing additional services to new and existing clients. We’ve had a mini restructure when spinning out Adjutor Clinical and hired the wonderful Kim Mitchell as Head of Clinical, and the talented Rama Gitifar as Head of Development, Regulatory and Commercialisation (DRC). Deb Cooper is now only wearing one hat, COO.
We’ve travelled, transformed, innovated, and made a real difference to companies on their product development and commercialisation journeys.
While the international landscape remains uncertain, our experience is that those who want to make a difference, keep doing just that. We don’t wait for things to “settle down”, we keep moving forward with initiative and resilience. The Adjutor Group is proudly entering another strong growth phase, with scalable, secure systems, and a strong talent pool in our Operations and Business Development functions.
We’re looking forward to 2026 with great excitement about what we can achieve for our clients, and for patients who so badly need access to new therapies, through clinical trials and approved products coming to market.
I wish friends and colleagues, both old and new, a very happy and safe Christmas holiday break.
Here is what I’ll be reading and watching:
GK Chesteron – The Father Brown Diaries
Michael Bungay Stanier – The Coaching Habit (re-reading)
Stranger Things – Series 5
Rematch – Miniseries
Blue Moon – Movie
Dr Rosalie Cull
CEO Adjutor Healthcare Pty Ltd
Key Milestones of 2025
2025 was marked by several significant achievements:
A New Chapter: Launched Adjutor Clinical a new boutique CRO providing fast, cost-effective trial start-up and end-to-end support.
Team Growth: Celebrated new talent joining our team, enhancing our skills and expertise.
Leading Through Engagement: Participated in industry events as speakers and presenters, sharing insights and expertise while driving innovation across the healthcare ecosystem.
Client Growth: Welcomed numerous new clients while supporting our existing clients in their new and ongoing projects.
Consolidated our service offering in China.
The Official Launch: Adjutor Clinical
In 2025 we proudly launched Adjutor Clinical in response to strong client demand and a growing portfolio of clinical projects. This new venture builds on the expertise and trusted relationships established by Adjutor Healthcare and our team over many years, and will focus on delivering responsive, high quality, tailored, CRO services, to support our clients and partners.
Adjutor Clinical is a full service CRO providing end-to-end clinical development support including study design, pre-IND and IND services, site selection, permits and regulatory/ethics approvals, clinical trial monitoring, data management, biostatistics and clinical study report writing. More information on the full range of services is available on our website under Our Services.
What makes Adjutor Clinical different?
Specialist in Early-Stage and Bridging Studies: Although we can support clients across all phases of research, we specialise in early-phase clinical development and bridging studies, allowing us to deliver scientific insight, tailored operational strategies, and faster, higher-quality outcomes. Our expertise ensures that early decisions are data-driven and that projects transition smoothly into later phases.
High Quality Project Management: Our flat, flexible organisation enables rapid issue resolution and faster execution. With fewer layers and direct access to decision-makers, we move quickly, because time is a critical resource for our clients and for the patients waiting for new therapies.
Passion for the Patient Journey: At the heart of our work is a genuine commitment to improving patient outcomes. We design and operate studies with empathy, clarity, and respect for participants, prioritising patient experience, safety, and engagement at every step.
Deep Understanding of the Local Ecosystem: We possess an extensive knowledge of the local operational landscape. Our team understands how to navigate local requirements efficiently, anticipate challenges, and leverage local opportunities to enhance study start up and operations.
Established Relationships with High-Performing Sites: We maintain long-standing relationships with key clinical sites and investigators, enabling faster site identification, smoother start-up, and higher enrolment performance. Our established trust with site teams helps reduce delays and supports strong patient recruitment outcomes.
Fast start up, efficient and effective project management: By leveraging our structure and optimising resources, we can deliver innovative and flexible cost solutions, whilst ensuring high quality standards.
Clinical Development Services
Clinical Trial Services
Adjutor Clinical provides comprehensive clinical trial services for medicines, medical devices and cell and gene therapies.
We’re also excited to spotlight our brand new website, a refreshed platform that now clearly showcases both the services being offered by Adjutor Clinical and Adjutor Healthcare. With a clean design and improved navigation, the site offers a more intuitive way to explore our services, meet our team, and stay up to date with the latest developments across the organisation and sector.
In addition, we’ve enhanced our Contact Us page, complete with prompts and questions designed to help us better serve our clients and partner.
The new website enhances navigation, strengthens our brand, and provides visitors with a seamless, informative experience from the moment they arrive.
Representing Melbourne: Joining the Lord Mayor’s Delegation to China and Japan
In September, the Lord Mayor of Melbourne led a delegation to China and Japan to strengthen economic, cultural, and innovation ties with key Asian cities, including Tianjin, Chengdu, Nanjing, Osaka, and Tokyo.
Each city demonstrated unique capabilities, Tianjin’s large-scale biomedical manufacturing, Chengdu’s growing life-sciences and clinical research ecosystem (and the Giant pandas), Nanjing’s strong academic and biotech research base, Osaka’s established pharmaceutical and regenerative medicine industries, and Tokyo’s leadership in digital health and advanced medical technologies.
The mission focused on trade, investment, sustainability, urban design, and knowledge exchange, and marked the 45th anniversary of Melbourne’s sister-city relationship with Tianjin, a milestone we were proud to help celebrate.
This visit has reinforced our understanding of the local landscape and strengthened the connections that matter. We return better equipped and inspired to support our clients with meaningful on-the-ground insight.
Local Engagement: Building Collaboration, Insight, and Connection
Building on a strong year in 2024, our local engagement efforts have continued to deepen relationships across industry, government, and partners.
Our active participation in leading industry events across Australia, including:
ARCS Regulatory Summit (Canberra, Feb 2025)
ARCS PV Summit (Sydney, Mar 2025)
BioMelbourne Network Connecting Women Lunch (Melbourne, May 2026)
AusMedTech (Sydney, May 2025), and AusMedTech Invest (Sydney, May 2025)
ARCS Annual Conference (Sydney, June 2025)
ACBC Health Tech Summit (Melbourne, Jul 2025)
ISCT ANZ Regional Meeting (Sydney, Aug 2025)
AusBioInvest (Melbourne, Oct 2025)
AusBiotech (Melbourne, Oct 2025).
Our involvement in the AusBiotech NSW Working Group this year further strengthened our commitment to shaping the future of Australia’s life-sciences ecosystem. By contributing to collaborative discussions and strategic initiatives, we’re helping to drive more coordinated industry growth and ensure that innovation continues to thrive across the sector. This work not only reflects our dedication to the community but also positions us to better support our clients and partners as the landscape evolves. Reach out to our representative, Joe Badolato, if you would like matters raised.
In 2025, our team (both in person and virtually) engaged in multiple industry symposiums, workshops, and fireside conversations, while also being invited to present as guest and keynote speakers across several prominent sector events.
In New Zealand:Meeting on the Med (Virtual, Apr 2025) NZACRes (Auckland, Aug 2025) demonstrates our commitment to remaining at the forefront of industry innovation and regional trends.
By participating in these events, we stay at the forefront of industry knowledge and innovation, while encouraging collaborative relationships that create meaningful solutions for our clients and partners. Every engagement underscores our commitment to advancing the sector and supporting the broader global healthcare ecosystem.
Our Commitment to Insight and Learning
We strengthened our commitment to knowledge-sharing with regular blog updates.
Voices of Our Clients: Insights That Drive Us Forward
This year, we were proud to receive invaluable feedback from our clients and partners, insights that continue to shape and strengthen the way we work. Hearing directly from those we support not only validates the impact of our efforts but also highlights opportunities to evolve, innovate, and deliver even greater value. Their perspectives are essential in guiding our growth, refining our services, and ensuring we consistently meet the needs of a dynamic and rapidly advancing industry.
Team News:
2025 A Year in Review: Our end of year get together gave our team the chance to reflect on our achievements, growth, and progress we’ve made together this year.
Celebrating New Talent:
The Adjutor Group is proud to welcome Kim Mitchell, Rama Gitifar, and Rob Parbery to the team.
We’re also excited to welcome additional team members in early 2026, continuing to grow our SME capabilities and talent pool.
“What excites me most about joining Adjutor Healthcare is the opportunity to contribute to a place that combines expertise with a strong sense of purpose. It’s not a place where teams simply ‘tick regulatory boxes. It’s a place that thinks, challenges, anticipates and collaborates.”
Head of Development, Regulatory and Commercialisation
“With a focus on patient outcomes, Adjutor Clinical is at an exciting phase, partnering with existing and new clients to manage and deliver clinical development programs. Australia and New Zealand offer exceptional advantages for conducting clinical trials, and for me Adjutor Clinical provides the expertise to deliver with quality and responsiveness at every stage of development.”
“I’ve always been drawn to roles with diverse product portfolios. Moving into a consultancy role with Adjutor offers this, as well as the opportunity to contribute to real-world benefits and the chance to be part of a highly experienced team that values initiative, collaboration; the kind of setting I can make a meaningful contribution to and stretch my capabilities.”
The Adjutor Group is proud to support initiatives that make a real difference to individuals and communities. Through events such as International Women’s Day, Jeans for Genes Day, we promote inclusivity, raise awareness, and encourage positive change. By participating, we inspire our team, partners, and the wider community to act and help create a better tomorrow. Shout out to one of our Senior Consultants, Martie Van Heerdan for her long history of blood donation in New Zealand, saving and improving lives.
A highlight of our year has been the fun and creative team-building activities woven into our staff meetings. From sharing our playlists to sharing pictures of our favourite childhood toys, these moments have brought us together, strengthened relationships, and added a sense of energy and enjoyment to our work. They’ve helped us stay connected, communicate better, and celebrate the unique strengths each person brings to the team.
Here are some fun and memorable moments from our team:
Having a ‘Teddy Bear Picnic’ as a farewell party for Wendy Cull.
Finding our most outrageous hats to wear to our weekly team meeting -honourable mention to Maureen Prosser, our Quality Manager for the chocolate lovers’ hat, and Office Manager Emma Camilleri for the hand-crocheted frog hat.
Partnering for the Future of Healthcare
Thank you for being part of our year. With stronger foundations, deeper insights, and renewed focus, we’re ready to make next year our best yet. Visit our updated website, engage with our expert team, and see how The Adjutor Group, your trusted healthcare partner, can provide end-to-end support across every stage, from clinical development and regulatory strategy through to successful registration, commercialisation, and navigation of an ever-evolving healthcare landscape.
Contact us to learn more about how we can work together to create impactful solutions for the future.
Emerging Regulatory Frameworks for Programmable Immune Engineering Introduction In vivo CAR‑T therapy represents one of the most scientifically disruptive developments in modern biotechnology. Unlike traditional CAR‑T therapies, where T cells are removed from the patient, genetically engineered ex vivo, expanded, and reinfused, in vivo CAR‑T platforms aim to genetically program immune cells directly inside the…
How Smart Biotech Companies Are Winning in Accelerated Global Approval Pathways The global biotechnology regulatory environment is no longer just accelerating, it is fragmenting into a set of strategic choices that materially impact time to market, capital efficiency, and valuation. Companies that actively design multi-market regulatory strategies early are gaining measurable advantages. Those that don’t…
How Australia Accelerates Global Development A Maturing Global Rare Disease Landscape. In rare diseases, time equals patient impact. Leveraging Australia’s advantages enables faster, smarter global development. What are Orphan and Rare Diseases? Orphan and rare diseases are conditions that affect a small percentage of the population, often defined as impacting fewer than 1 in 2,000…
We use cookies to ensure that we give you the best experience on our website.
